Amoxapine is a tricyclic antidepressant (TCA) that was FDA-approved in the United States in 1980 for the treatment of depression, including depression accompanied by anxiety or agitation. Unlike many other tricyclics, amoxapine has a unique dual-action mechanism — it functions as both a norepinephrine reuptake inhibitor and a dopamine receptor antagonist, giving it mild antipsychotic properties in addition to its antidepressant effects.
While newer antidepressants like SSRIs and SNRIs have largely replaced tricyclics as first-line treatments, amoxapine remains a useful option for certain patients — particularly those who have not responded to newer medications or who have depression with psychotic features.
Amoxapine works primarily by blocking the reuptake of norepinephrine, increasing the availability of this neurotransmitter at nerve synapses. It also blocks dopamine D2 receptors — a mechanism shared with antipsychotic medications. This dual action is what distinguishes amoxapine from other tricyclic antidepressants and makes it particularly useful for depression with psychotic features (delusions, hallucinations, or severe paranoia accompanying depression).
Amoxapine is actually a metabolite of the antipsychotic loxapine, which explains its dopamine-blocking properties. It has relatively weak anticholinergic effects compared to other tricyclics, which means it may cause fewer side effects like dry mouth, constipation, and urinary retention.
Amoxapine is primarily prescribed for major depressive disorder, depression with psychotic features (where its dopamine-blocking action provides antipsychotic coverage without requiring a separate antipsychotic medication), treatment-resistant depression that has not responded to SSRIs or SNRIs, and depression with significant anxiety or agitation (its sedating properties can be beneficial). Because amoxapine addresses both depressive and psychotic symptoms simultaneously, it can simplify medication regimens for patients who would otherwise need both an antidepressant and an antipsychotic.
The usual starting dose of amoxapine is 50 mg two to three times daily (100-150 mg/day total). The dose may be gradually increased to 200-300 mg daily, with a maximum recommended dose of 400 mg daily for outpatients and 600 mg daily for hospitalized patients. Most of the therapeutic dose can be given at bedtime due to amoxapine's sedating effects, which can help patients who also have insomnia.
Amoxapine has a relatively rapid onset of action compared to other tricyclics — some patients report improvement within the first week, with clinically meaningful effects typically appearing within 2-3 weeks.
Common side effects include drowsiness and sedation (often beneficial for patients with insomnia), dry mouth, constipation, weight gain, blurred vision, dizziness upon standing (orthostatic hypotension), and increased appetite. Because of its dopamine-blocking activity, amoxapine can also cause movement-related side effects that are not typical of other antidepressants, including muscle stiffness or rigidity, restlessness (akathisia), and in rare cases with prolonged use, tardive dyskinesia (involuntary movements).
The risk of movement side effects is lower than with traditional antipsychotics but higher than with other antidepressants. This is an important consideration when weighing the benefits and risks of amoxapine versus other treatment options.
Like all tricyclic antidepressants, amoxapine requires careful monitoring. It has a narrow therapeutic window, meaning the difference between an effective dose and a toxic dose is smaller than with newer antidepressants. Overdose can be serious and potentially fatal — a critical consideration for patients with suicidal ideation. Amoxapine should not be combined with MAOIs due to the risk of hypertensive crisis. It can lower the seizure threshold, so it should be used cautiously in patients with a history of seizures. It may affect cardiac conduction, so an ECG may be recommended before starting treatment, particularly in older adults.
Modern antidepressants like SSRIs (fluoxetine, citalopram, sertraline) and SNRIs are generally preferred as first-line treatments because they have better safety profiles, fewer side effects, and are safer in overdose. Wellbutrin (bupropion) offers another alternative with a different mechanism of action.
However, amoxapine has specific advantages in certain clinical scenarios: its dual antidepressant-antipsychotic action is unique among antidepressants, it works faster than many alternatives, and it can be effective when newer medications have failed. For patients with psychotic depression, amoxapine can simplify treatment by addressing both symptoms with a single medication rather than requiring a combination of drugs.
Amoxapine is typically considered when first-line antidepressants have not been effective or when the clinical picture includes psychotic features alongside depression. The decision to use amoxapine should be made in close collaboration with a psychiatrist who can weigh the potential benefits against the risks and monitor for side effects.
If you have depression that has not responded to other treatments, the board-certified psychiatrists at Elevate Psychiatry can provide a comprehensive evaluation and discuss all available treatment options — including older medications like amoxapine that may be appropriate for your situation. We offer in-person appointments in Miami and virtual visits throughout Florida. Schedule your consultation today.
This content is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or changing any medication.
Amoxapine is a tricyclic antidepressant used primarily for major depressive disorder. Its unique dopamine-blocking properties make it especially useful for depression with psychotic features and treatment-resistant depression.
Amoxapine has both antidepressant and mild antipsychotic properties due to its dopamine D2 receptor blocking activity. This dual mechanism is unique among antidepressants and makes it useful for psychotic depression without needing a separate antipsychotic.
Amoxapine has a relatively fast onset compared to other tricyclics. Some patients notice improvement within the first week, with clinically meaningful effects typically appearing within 2-3 weeks — faster than many SSRIs.
Yes, though less commonly than newer antidepressants. It is typically reserved for patients who have not responded to SSRIs or SNRIs, or who have depression with psychotic features where its dual mechanism provides an advantage.
Common side effects include drowsiness, dry mouth, constipation, weight gain, and dizziness. Unlike other antidepressants, amoxapine can also cause movement-related side effects like muscle stiffness due to its dopamine-blocking activity.
In rare cases with prolonged use, amoxapine can cause tardive dyskinesia (involuntary movements) due to its dopamine-blocking properties. This risk is lower than with traditional antipsychotics but higher than with other antidepressants.
